|
1
|
Ravdin PM and Chamness GC: The c-erbB-2
proto-oncogene as a prognostic and predictive marker in breast
cancer: A paradigm for the development of other macromolecular
markers-a review. Gene. 159:19–27. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dawood S, Broglio K, Buzdar AU, Hortobagyi
GN and Giordano SH: Prognosis of women with metastatic breast
cancer by HER2 status and trastuzumab treatment: An
institutional-based review. J Clin Oncol. 28:92–98. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ross JS, Slodkowska EA, Symmans WF,
Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and
breast cancer: Ten years of targeted anti-HER-2 therapy and
personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Junttila TT, Akita RW, Parsons K, Fields
C, Lewis Phillips GD, Friedman LS, Sampath D and Sliwkowski MX:
Ligand-independent HER2/HER3/PI3K complex is disrupted by
trastuzumab and is effectively inhibited by the PI3K inhibitor
GDC-0941. Cancer Cell. 15:429–440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molina MA, Codony-Servat J, Albanell J,
Rojo F, Arribas J and Baselga J: Trastuzumab (Herceptin), a
humanized anti-Her2 receptor monoclonal antibody, inhibits basal
and activated Her2 ectodomain cleavage in breast cancer cells.
Cancer Res. 61:4744–4749. 2001.PubMed/NCBI
|
|
7
|
Beano A, Signorino E, Evangelista A, Brusa
D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, Ciuffreda L and
Matera L: Correlation between NK function and response to
trastuzumab in metastatic breast cancer patients. J Transl Med.
6:252008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barok M, Isola J, Pályi-Krekk Z, Nagy P,
Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G and
Szöllösi J: Trastuzumab causes antibody-dependent cellular
cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1
breast cancer xenografts despite intrinsic drug resistance. Mol
Cancer Ther. 6:2065–2072. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marty M, Cognetti F, Maraninchi D, Snyder
R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A,
et al: Randomized phase II trial of the efficacy and safety of
trastuzumab combined with docetaxel in patients with human
epidermal growth factor receptor 2-positive metastatic breast
cancer administered as first-line treatment: The M77001 study
group. J Clin Oncol. 23:4265–4274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Franklin MC, Carey KD, Vajdos FF, Leahy
DJ, de Vos AM and Sliwkowski MX: Insights into ErbB signaling from
the structure of the ErbB2-pertuzumab complex. Cancer Cell.
5:317–328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Agus DB, Akita RW, Fox WD, Lewis GD,
Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K,
et al: Targeting ligand-activated ErbB2 signaling inhibits breast
and prostate tumor growth. Cancer Cell. 2:127–137. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamashita-Kashima Y, Iijima S, Yorozu K,
Furugaki K, Kurasawa M, Ohta M and Fujimoto-Ouchi K: Pertuzumab in
combination with trastuzumab shows significantly enhanced antitumor
activity in HER2-positive human gastric cancer xenograft models.
Clin Cancer Res. 17:5060–5070. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scheuer W, Friess T, Burtscher H,
Bossenmaier B, Endl J and Hasmann M: Strongly enhanced antitumor
activity of trastuzumab and pertuzumab combination treatment on
HER2-positive human xenograft tumor models. Cancer Res.
69:9330–9336. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baselga J, Cortés J, Kim SB, Im SA, Hegg
R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al:
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast
cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Swain SM, Kim SB, Cortés J, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for
HER2-positive metastatic breast cancer (CLEOPATRA study): Overall
survival results from a randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kurebayashi J, Otsuki T, Tang CK, Kurosumi
M, Yamamoto S, Tanaka K, Mochizuki M, Nakamura H and Sonoo H:
Isolation and characterization of a new human breast cancer cell
line, KPL-4, expressing the Erb B family receptors and
interleukin-6. Br J Cancer. 79:707–717. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kunisue H, Kurebayashi J, Otsuki T, Tang
CK, Kurosumi M, Yamamoto S, Tanaka K, Doihara H, Shimizu N and
Sonoo H: Anti-HER2 antibody enhances the growth inhibitory effect
of anti-oestrogen on breast cancer cells expressing both oestrogen
receptors and HER2. Br J Cancer. 82:46–51. 2000.PubMed/NCBI
|
|
19
|
Le XF, McWatters A, Wiener J, Wu JY, Mills
GB and Bast RC Jr: Anti-HER2 antibody and heregulin suppress growth
of HER2-overexpressing human breast cancer cells through different
mechanisms. Clin Cancer Res. 6:260–270. 2000.PubMed/NCBI
|
|
20
|
Lane HA, Beuvink I, Motoyama AB, Daly JM,
Neve RM and Hynes NE: ErbB2 potentiates breast tumor proliferation
through modulation of p27Kip1-Cdk2 complex formation: Receptor
overexpression does not determine growth dependency. Mol Cell Biol.
20:3210–3223. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yakes FM, Chinratanalab W, Ritter CA, King
W, Seelig S and Arteaga CL: Herceptin-induced inhibition of
phosphatidylinositol-3 kinase and Akt is required for
antibody-mediated effects on p27, cyclin D1, and antitumor action.
Cancer Res. 62:4132–4141. 2002.PubMed/NCBI
|
|
22
|
Ringel I and Horwitz SB: Studies with RP
56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer
Inst. 83:288–291. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dang C, Iyengar N, Datko F, D'Andrea G,
Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M,
et al: Phase II study of paclitaxel given once per week along with
trastuzumab and pertuzumab in patients with human epidermal growth
factor receptor 2-positive metastatic breast cancer. J Clin Oncol.
33:442–447. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Piechocki MP, Yoo GH, Dibbley SK and
Lonardo F: Breast cancer expressing the activated HER2/neu is
sensitive to gefitinib in vitro and in vivo and acquires resistance
through a novel point mutation in the HER2/neu. Cancer Res.
67:6825–6843. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamashita-Kashima Y, Shu S, Harada N and
Fujimoto-Ouchi K: Enhanced antitumor activity of trastuzumab
emtansine (T-DM1) in combination with pertuzumab in a HER2-positive
gastric cancer model. Oncol Rep. 30:1087–1093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang Y, Yu T, Fu X, Chen J, Liu Y, Li C,
Xia Y, Zhang Z and Li L: EGFR inhibition prevents in vitro tumor
growth of salivary adenoid cystic carcinoma. BMC Cell Biol.
14:132013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Melichar B, Študentova H, Kalábová H,
Vitásková D, Čermáková P, Hornychová H and Ryška A: Predictive and
prognostic significance of tumor-infiltrating lymphocytes in
patients with breast cancer treated with neoadjuvant systemic
therapy. Anticancer Res. 34:1115–1125. 2014.PubMed/NCBI
|
|
28
|
Zardavas D, Fouad TM and Piccart M:
Optimal adjuvant treatment for patients with HER2-positive breast
cancer in 2015. Breast. 24:(Suppl 2). S143–S148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Loi S, Michiels S, Salgado R, Sirtaine N,
Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V,
Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in
triple negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: Results from the FinHER trial. Ann
Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsavaris N, Kosmas C, Vadiaka M,
Kanelopoulos P and Boulamatsis D: Immune changes in patients with
advanced breast cancer undergoing chemotherapy with taxanes. Br J
Cancer. 87:21–27. 2002. View Article : Google Scholar : PubMed/NCBI
|
